https://ansm.sante.fr/tableau-marr/eliglustat 2023 false false false France French risk management eliglustat guidelines for drug use drug interactions
--- eliglustat https://www.ema.europa.eu/medicines/human/EPAR/Cerdelga 2015 false false false United Kingdom French English treatment outcome syndication feed summary of product characteristics package leaflet drug evaluation eliglustat eliglustat eliglustat drug approval europe gaucher disease, type 1 adult orphan drug production rare diseases administration, oral enzyme inhibitors enzyme inhibitors drug monitoring risk management product surveillance, postmarketing drug interactions breast feeding pregnancy ceramide glucosyltransferase drug evaluation, preclinical gaucher disease pyrrolidines pyrrolidines glucosyltransferases
--- http://www.has-sante.fr/portail/jcms/c_2572136/fr/cerdelga 2015 false false false false France French evaluation of the transparency committee treatment outcome administration, oral eliglustat tartrate eliglustat tartrate eliglustat gaucher disease, type 1 enzyme inhibitors enzyme inhibitors adult orphan drug production CYP2D6 gene status assay cytochrome p-450 cyp2d6 ceramide glucosyltransferase risk management gaucher disease eliglustat eliglustat gaucher disease pyrrolidines pyrrolidines glucosyltransferases